Skip to main content

Table 3 change assessment at each group

From: Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis

Group

Mean

Std. Deviation

Paired t

P

Group1

FVC (ml)

1287.6000

106.79760

− 0.990

0.3125

FVC (ml) 6M

1265.5530

215.15587

  

FVC%predicted

55.7500

4.26584

0.340

0.814

FVC%predicted 6M

53.8500

6.42589

  

6MWT (m)

287.5000

33.06692

1.785

0.0674

6MWT (m) 6M

310.0000

74.09809

  

PaO2 at rest

64.7500

2.31414

− 1.653

0.0881

PaO2 at rest 6M

66.0500

2.81864

  

SaO2

93.5000

2.48151

1.245

0.124

SaO2 6M

94.1500

3.52846

  

PAP

35.0000

7.36278

1.085

0.231

PAP 6M

33.0000

6.56947

  

SGRQ SCORE

37.2000

1.43637

1.106

0.224

SGRQ SCORE 6M

38.2500

2.35123

  

Group2

FVC (ml)

1276.0000

106.74120

4.745

0.00**

FVC (ml) 6M

1100.5000

109.46160

  

FVC%predicted

57.4500

6.16542

1.879

0.052

FVC%predicted 6M

48.5000

4.53640

  

6MWT

290.0000

28.83711

4.314

0.00**

6MWT 6M

267.0000

37.98892

  

PaO2 at rest

62.8500

4.24605

3.088

0.002*

PaO2 at rest 6M

54.9000

3.53777

  

SaO2

92.5000

2.65370

− 5.139

0.00**

SaO2 6M

87.0000

3.07794

  

PAP

33.2500

5.74800

− 2.019

0.048*

PAP 6M

36.8000

5.95686

  

SGRQ SCORE

37.8500

2.42441

− 3.795

0.00**

SGRQ SCORE 6M

44.5000

2.35627

  
  1. *refer to significant results
  2. **refer to highly significant results
  3. FVC forced vital capacity, 6MWT 6 minutes walking test, PaO2 partial pressure of oxygen in arterial blood, SaO2 oxygen saturation in arterial blood, PAP pulmonary artery pressure, SGRQ St. George’s Respiratory Questionnaire